Reports Q4 revenue $298M, consensus $259.3M. The company said, “Indivior (INDV) ended 2024 with a better-than-expected fourth quarter performance that put our FY 2024 results ahead of our October guidance. While we delivered 20% year-on-year NR growth in SUBLOCADE, our 2024 performance was impacted by previously disclosed transitory items and competition in the U.S. long-acting injectable category. As shared in our Q3 results, we have narrowed our strategic focus to meeting opioid use disorder patients’ unmet needs with SUBLOCADE, OPVEE and a strong pipeline of Phase II assets. As a result, we streamlined our cost base and identified savings exceeding $100m of which approximately $50m will be reinvested behind SUBLOCADE and our OUD-focused pipeline and over $50m will help protect our adjusted operating profit.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INDV:
- Indivior Reports Revenue Growth in 2024, Faces Challenges in 2025 Outlook
- INDV Earnings this Week: How Will it Perform?
- Indivior weakness on delay a buying opportunity, says Northland
- Indivior announces FDA delay of final review of Sublocade label changes
- Indivior Faces FDA Delay on SUBLOCADE Label Changes